News & Events

Results of Operations and Financial Condition. First Quarter 2026 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On April 30, 2026 , the Company issued a press release announcing its unaudited results of operations for the three months ended March 31, 2026, and its unaudited financial position as of March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Acco…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer. To facilitate the further integration of our science, technology and data and build on the strong alignment of our commercial, medical and policy teams, the responsibi…

Entry into a Material Definitive Agreement. On February 17, 2026, Amgen Inc. (the “Company”) issued and sold $1,000,000,000 aggregate principal amount of the Company’s 4.200% Senior Notes due 2031 (the “2031 Notes”), $1,750,000,000 aggregate principal amount of the Company’s 4.850% Senior Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of the Company’s 5.500% Senior Notes due 2046 (the “2046 Notes”) and $750,000,000 aggregate principal amount of the Company’s 5.650%…

Results of Operations and Financial Condition. Fourth Quarter and Full Year 2025 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On February 3, 2026 , the Company issued a press release announcing its unaudited results of operations for the three months and year ended December 31, 2025, and its unaudited financial position as of December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain…

Termination of a Material Definitive Agreement. On January 30, 2026, Amgen Inc. (the “ Company ”) entered into a Termination Agreement (the “ Termination Agreement ”) with Kyowa Kirin Co., Ltd. (“ Kyowa Kirin ”), pursuant to which the Company and Kyowa Kirin agreed to terminate the License and Collaboration Agreement, dated June 1, 2021 (the “ License and Collaboration Agreement ”). The termination of the License and Collaboration Agreement will become effective upon receipt of regulatory app…

Results of Operations and Financial Condition. Third Quarter 2025 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On November 4, 2025 , the Company issued a press release announcing its unaudited results of operations for the three and nine months ended September 30, 2025, and its unaudited financial position as of September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Gene…

Results of Operations and Financial Condition. Second Quarter 2025 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On August 5, 2025 , the Company issued a press release announcing its unaudited results of operations for the three and six months ended June 30, 2025, and its unaudited financial position as of June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accept…

Results of Operations and Financial Condition. First Quarter 2025 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On May 1, 2025 , the Company issued a press release announcing its unaudited results of operations for the three months ended March 31, 2025, and its unaudited financial position as of March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Account…

Results of Operations and Financial Condition. Fourth Quarter and Full Year 2024 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On February 4, 2025 , the Company issued a press release announcing its unaudited results of operations for the three months and year ended December 31, 2024, and its unaudited financial position as of December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain…

Results of Operations and Financial Condition. Third Quarter 2024 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On October 30, 2024 , the Company issued a press release announcing its unaudited results of operations for the three and nine months ended September 30, 2024, and its unaudited financial position as of September 30, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Gene…

Results of Operations and Financial Condition. Second Quarter 2024 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On August 6, 2024 , the Company issued a press release announcing its unaudited results of operations for the three and six months ended June 30, 2024, and its unaudited financial position as of June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accept…

Results of Operations and Financial Condition. First Quarter 2024 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On May 2, 2024 , the Company issued a press release announcing its unaudited results of operations for the three months ended March 31, 2024, and its unaudited financial position as of March 31, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Account…

Results of Operations and Financial Condition. Fourth Quarter 2023 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On February 6, 2024, the Company issued a press release announcing its unaudited results of operations for the three months and year ended December 31, 2023, and its unaudited financial position as of December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Genera…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. David M. Reese, M.D., will transition from Executive Vice President, Research and Development to Executive Vice President and Chief Technology Officer, a newly created executive officer position, responsible for accelerating the use of technology and artificial intelligence (AI) across all facets of Amgen Inc. (“Amgen” or the “Company”). James Brad…

Results of Operations and Financial Condition. Third Quarter 2023 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On October 31, 2023 , the Company issued a press release announcing its unaudited results of operations for the three and nine months ended September 30, 2023, and its unaudited financial position as of September 30, 2023. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Gene…

Completion of Acquisition or Disposition of Assets. The Acquisition was conditioned on, among other things, the sanction of the Scheme by the Irish High Court (the “ Court ”) and the delivery of the Court Order (as defined in the Transaction Agreement) to the Registrar of Companies in Dublin, Ireland. On October 5, 2023, the Court sanctioned the Scheme. On October 6, 2023, the Court Order was delivered to the Registrar of Companies, at which time the Scheme became effective (the “ Effective T…

Creation of a Direct Financial Obligation or an Obligation Under an Off- Balance Sheet Arrangement of a Registrant. As previously reported, on December 22, 2022, Amgen entered into a Term Loan Credit Agreement (the “ Term Loan Credit Agreement ”) among Amgen, Citibank, N.A. (“ Citibank ”), as administrative agent, Bank of America, N.A. (“ Bank of America ”), as syndication agent, Citibank, Bank of America, Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, and G…

Other Events As previously disclosed, Amgen Inc. (“ Amgen ”), Pillartree Limited, a private limited company incorporated under the laws of Ireland and a wholly owned subsidiary of Amgen (“ Acquirer Sub ”), and Horizon Therapeutics plc (“ Horizon ”) entered into that certain Transaction Agreement, dated as of December 11, 2022, pursuant to which, among other things, Acquirer Sub will acquire the entire issued ordinary share capital of Horizon (the “ Acquisition ”) through a court-sanctioned sc…

Other Events As previously disclosed, on September 1, 2023, Amgen Inc. (“Amgen”) and Horizon Therapeutics plc (“Horizon”) announced the entry into a consent order agreement with the Federal Trade Commission (the “FTC”) that resolves the pending FTC administrative lawsuit related to the previously announced acquisition of Horizon (the “Acquisition”). Later on September 1, 2023, the U.S. District Court for the Northern District of Illinois granted the stipulated proposed orders that were jointl…

Other Events On September 1, 2023, Amgen and Horizon announced the entry into a consent order agreement with the Federal Trade Commission (the “FTC”) that resolves the pending FTC administrative lawsuit related to the Acquisition. As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Nort…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) and (c). On August 1, 2023, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Matthew C. Busch, age 49, to serve as the Company’s Vice President, Finance and Chief Accounting Officer (“CAO”), effective August 14, 2023. Mr. Busch will be the Company’s principal accounting officer; he will not be an executive officer of…

Results of Operations and Financial Condition. Second Quarter 2023 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On August 3, 2023 , the Company issued a press release announcing its unaudited results of operations for the three and six months ended June 30, 2023, and its unaudited financial position as of June 30, 2023. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accept…

is in accordance with the facts and does not omit anything likely to affect the import of such information. -1- Forward-Looking Statements This Current Report on Form 8-K contains certain statements about Horizon and Amgen that are or may be forward-looking statements which include, but are not limited to, statements regarding expected timing, completion and effects of the Acquisition. These forward-looking statements are subject to the safe harbor provisions under the U.S. Private Securities…

Other Events As previously disclosed, on December 11, 2022, Amgen Inc. (“Amgen”), Horizon Therapeutics plc (“Horizon”) and Pillartree Limited, a wholly owned subsidiary of Amgen (“Acquirer Sub”), entered into a Transaction Agreement, dated December 11, 2022, pursuant to which, among other things, Acquirer Sub will acquire the entire issued ordinary share capital of Horizon (the “Acquisition”). As also previously disclosed, on May 16, 2023, the U.S. Federal Trade Commission (“FTC”) filed a com…

Regulation FD Disclosure As previously disclosed, on December 11, 2022, Amgen Inc. (“Amgen”), Horizon Therapeutics plc (“Horizon”) and Pillartree Limited, a wholly owned subsidiary of Amgen (“Acquirer Sub”), entered into a Transaction Agreement, dated December 11, 2022, pursuant to which, among other things, Acquirer Sub will acquire the entire issued ordinary share capital of Horizon (the “Acquisition”). On May 16, 2023, the U.S. Federal Trade Commission filed a complaint in the United State…